Liver-directed AAV gene therapy for PHKG2-Glycogen Storage Disease IX (GSD IX y2)

针对 PHKG2-糖原贮积病 IX (GSD IX y2) 的肝脏定向 AAV 基因治疗

基本信息

  • 批准号:
    10700162
  • 负责人:
  • 金额:
    $ 5.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Liver Glycogen Storage Disease type IX has an overall estimated prevalence of 1 in 100,000 individuals, accounting for approximately 25% of all GSD cases. Liver GSD IX is caused by deficiency of the liver enzyme phosphorylase kinase (PhK) and presents with hepatomegaly, elevated liver enzymes, and hypoglycemia. PhK is a complex, hetero-tetrameric enzyme comprised of four subunits - α, β, γ, and δ - each with tissue specific isoforms encoded by different genes. The genes PHKA2, PHKB, and PHKG2 encode the liver specific isoform PhK subunits α2, β, and γ2 respectively. Until the recent availability of gene panels and exome sequencing, the diagnosis of Liver GSD IX did not allow for differentiation of these subtypes. There is growing evidence that patients with the second most common subtype, PHKG2 GSD IX (GSD IX γ2) develop severe liver disease. Of published case reports, 95.8% of patients with GSD IX γ2 reported features of liver fibrosis and/or cirrhosis, placing individuals with GSD IX γ2 at higher risk for liver failure, hepatocellular carcinoma and death. Despite the life-threatening severity of GSD IX γ2, there has been minimal research to understand disease progression or options for treatment. The first goal of this project is to characterize the phenotype of the first mouse model of PHKG2 GSD IX (GSD IX γ2). Preliminary evidence from male and female 3-month-old Phkg2-/- mice is encouraging. I have discovered that knockout mice have significantly elevated liver glycogen content, serum ALP, AST, ALT, urine Hex4, and features of hepatocyte enlargement and fibrosis compared to wild type controls. I will continue to characterize the Phkg2-/- mouse phenotype at 6, 9- and 12-months of age. By identifying the time of onset and progression of liver disease in our model, I will better understand the ideal time to deliver therapy. The second goal of this project is to evaluate the efficacy of a novel AAV gene therapy approach for reducing liver disease progression in the Phkg2-/- mouse model. Current liver-directed gene therapies utilize a recombinant adeno-associated virus serotype 8 (AAV8), based on preclinical efficacy in mice. However, recent studies have demonstrated that AAV8 has greater tropism for murine versus human hepatocytes. Our group has identified a novel capsid with high transduction rates for both human and murine hepatocytes (AAVhum.8) – making it an excellent vector for preclinical evaluation with high potential for clinical translation. The results of this project will characterize the first GSD IX γ2 mouse model, will provide preclinical evidence for a non-surgical, long-term, therapeutic option for patients with GSD IX γ2, and will inform the treatment of other pediatric genetic liver diseases.
肝糖原累积病IX型的总体估计患病率为1/100,000,约占所有GSD病例的25%。肝GSD IX是由肝酶磷酸化酶激酶(PhK)缺乏引起的,表现为肝肿大、肝酶升高和低血糖。PhK是一种复杂的异源四聚体酶,由四个亚基- α、β、γ和δ -组成,每个亚基具有由不同基因编码的组织特异性同种型。基因PHKA 2、PHKB和PHKG 2分别编码肝脏特异性同种型PhK亚基α2、β和γ2。直到最近可用的基因面板和外显子组测序,肝GSD IX的诊断不允许区分这些亚型。越来越多的证据表明,患有第二种最常见亚型PHKG 2 GSD IX(GSD IX γ2)的患者会发生严重的肝脏疾病。在已发表的病例报告中,95.8%的GSD IX γ2患者报告了肝纤维化和/或肝硬化的特征,使GSD IX γ2患者的肝衰竭、肝细胞癌和死亡风险更高。尽管GSD IX γ2的严重程度危及生命,但了解疾病进展或治疗选择的研究很少。该项目的第一个目标是表征PHKG 2 GSD IX(GSD IX γ2)的第一个小鼠模型的表型。来自雄性和雌性3个月大Phkg 2-/-小鼠的初步证据令人鼓舞。我已经发现,与野生型对照相比,基因敲除小鼠具有显著升高的肝糖原含量、血清ALP、AST、ALT、尿Hex 4以及肝细胞增大和纤维化的特征。我将继续在6、9和12月龄时表征Phkg 2-/-小鼠表型。通过确定我们模型中肝病的发作和进展时间,我将更好地了解提供治疗的理想时间。该项目的第二个目标是评估一种新型AAV基因治疗方法在Phkg 2-/-小鼠模型中减少肝脏疾病进展的疗效。目前的肝脏定向基因疗法利用重组腺相关病毒血清型8(AAV 8),基于在小鼠中的临床前功效。然而,最近的研究已经证明,AAV 8对鼠肝细胞比对人肝细胞具有更大的向性。我们的研究小组已经确定了一种对人和鼠肝细胞都具有高转导率的新型衣壳(AAVhum.8)-使其成为具有高临床转化潜力的临床前评价的优秀载体。该项目的结果将表征第一个GSD IX γ2小鼠模型,将为GSD IX γ2患者的非手术,长期治疗选择提供临床前证据,并将为其他儿科遗传性肝病的治疗提供信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rebecca Anne Gibson其他文献

Rebecca Anne Gibson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rebecca Anne Gibson', 18)}}的其他基金

Liver-directed AAV gene therapy for PHKG2-Glycogen Storage Disease IX (GSD IX y2)
针对 PHKG2-糖原贮积病 IX (GSD IX y2) 的肝脏定向 AAV 基因治疗
  • 批准号:
    10315138
  • 财政年份:
    2021
  • 资助金额:
    $ 5.27万
  • 项目类别:

相似海外基金

Enhancing Structural Competency in School-Based Health Centers to Address LGBTQ+ Adolescent Health Equity
增强校本健康中心的结构能力,以解决 LGBTQ 青少年健康公平问题
  • 批准号:
    10608426
  • 财政年份:
    2023
  • 资助金额:
    $ 5.27万
  • 项目类别:
Application and feasability of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care - a pilot study
简短的数字筛查工具的应用和可行性,以解决儿科医疗中父母和青少年烟草和电子烟的使用问题 - 一项试点研究
  • 批准号:
    486580
  • 财政年份:
    2022
  • 资助金额:
    $ 5.27万
  • 项目类别:
    Studentship Programs
Co-design of an intervention to address alcohol use among adolescent boys and young men in Tanzania
共同设计一项干预措施,解决坦桑尼亚青春期男孩和年轻男性的饮酒问题
  • 批准号:
    MR/V032380/1
  • 财政年份:
    2022
  • 资助金额:
    $ 5.27万
  • 项目类别:
    Research Grant
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/1
  • 财政年份:
    2021
  • 资助金额:
    $ 5.27万
  • 项目类别:
    Research Grant
Application of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care
应用简短的数字筛查工具来解决儿科医疗中父母和青少年烟草和电子烟的使用问题
  • 批准号:
    455984
  • 财政年份:
    2021
  • 资助金额:
    $ 5.27万
  • 项目类别:
    Operating Grants
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/2
  • 财政年份:
    2021
  • 资助金额:
    $ 5.27万
  • 项目类别:
    Research Grant
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
  • 批准号:
    10057761
  • 财政年份:
    2020
  • 资助金额:
    $ 5.27万
  • 项目类别:
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
  • 批准号:
    10213683
  • 财政年份:
    2020
  • 资助金额:
    $ 5.27万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 5.27万
  • 项目类别:
Designing targeted interventions to address HIV vulnerabilities and improve clinical outcomes among conflict affected adolescent girls and young women under 25 in Northern Uganda
设计有针对性的干预措施,以解决乌干达北部受冲突影响的少女和 25 岁以下年轻妇女的艾滋病毒脆弱性并改善临床结果
  • 批准号:
    356145
  • 财政年份:
    2016
  • 资助金额:
    $ 5.27万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了